Related references
Note: Only part of the references are listed.Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer
Kyle G. Mitchell et al.
ANNALS OF THORACIC SURGERY (2020)
PIK3CA gene mutations in the helical domain correlate with high tumor mutation buraen and poor prognosis in metastatic breast carcinomas with late-line therapies
Yu Tang et al.
AGING-US (2020)
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype for updates and increased immunogenicity
Chengming Liu et al.
CANCER LETTERS (2020)
Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
Yuan Tang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability
Simon Heeke et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images
Akira Ono et al.
CANCER MEDICINE (2020)
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
G. Lamberti et al.
ANNALS OF ONCOLOGY (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma
Hui Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?
Michael L. Cheng et al.
CLINICAL CANCER RESEARCH (2019)
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Michael Offin et al.
CLINICAL CANCER RESEARCH (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Saori Mishima et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
Optimizing panel-based tumor mutational burden (TMB) measurement
J. Budczies et al.
ANNALS OF ONCOLOGY (2019)
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
Tao Jiang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
Dedong Cao et al.
ONCOIMMUNOLOGY (2019)
A Composite Model Integrating Imaging, Histological, and Genetic Features to Predict Tumor Mutation Burden in Non-Small Cell Lung Cancer Patients
N. Zhang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
370PTumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Y-S Zang et al.
ANNALS OF ONCOLOGY (2019)
Mutation profiling of cancer drivers in Brazilian colorectal cancer
Wellington dos Santos et al.
SCIENTIFIC REPORTS (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Correlation analysis between PD-L1 expression, TMB and clinical characteristics in Chinese non-small cell lung cancer
Yang Yu et al.
CANCER RESEARCH (2019)
NR1 and NR3B Composed Intranuclear N-methyl-D-aspartate Receptor Complexes in Human Melanoma Cells
Tibor Hajdu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report
Yuki Owada-Ozaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Wantong Song et al.
NATURE COMMUNICATIONS (2018)
Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin
Mackenzie K. Herroon et al.
SCIENTIFIC REPORTS (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer
Yong-Kui Zhang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
Revisions to the Tumor, Node, Metastasis staging of lung cancer (8th edition): Rationale, radiologic findings and clinical implications
Fernando U. Kay et al.
WORLD JOURNAL OF RADIOLOGY (2017)
Nrf2 signaling pathway: Pivotal roles in inflammation
Syed Minhaj Uddin Ahmed et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas
Yi-Ran Cai et al.
SCIENTIFIC REPORTS (2016)
Comprehensive gene analysis including next generation sequencing (NGS) study with immunological parameters to obtain the biomarkers for immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
Yuki Owada et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation
Kyuichi Kadota et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Micropapillary Lung Adenocarcinoma EGFR, K-ras, and BRAF Mutational Profile
Rosane De Oliveira Duarte Achcar et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma
MS Roh et al.
HISTOPATHOLOGY (2004)
Share Paper
